The government used an independent valuation benchmark of ₹75.99 per share after rejecting an earlier bid of ₹75 that fell short of the ₹94.42 reserve price
The Indian rupee fell past the 96-per-dollar mark during intra-day trade on Tuesday, hitting a two-month low as higher crude prices triggered worries in energy markets.
In the grey markets, shares of Mankind Pharma enjoyed a premium of Rs 90, which translated to a likely listing price of Rs 1,170 per share on the upper price band